The headline numbers for Ventas (VTR) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Ventas (VTR) came out with quarterly funds from operations (FFO) of $0.84 per share, beating the Zacks Consensus Estimate of $0.82 per share. This compares to FFO of $0.78 per share a year ago.
Get a deeper insight into the potential performance of Ventas (VTR) for the quarter ended March 2025 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
While VTR's Q1 earnings are likely to have benefited from favorable SHOP operating trends and a well-diversified tenant base, high interest expenses may have hurt it.
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Ventas (VTR) have what it takes?
Aging population, rising healthcare expenses, favorable outpatient visit trends and accretive investments in its research portfolio are likely to support VTR.
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Ventas (VTR) have what it takes?
Ventas is a well-run REIT that's experiencing high growth, particularly in its SHOP portfolio. It carries a strong balance sheet and management has resumed meaningful dividend growth. The recent dip in price has brought the yield to 3%. Combined with high single digit FFO/share growth, VTR could deliver potential market-beating total returns.
Rising healthcare expenditures and an aging population support VTR's senior housing operating portfolio despite competition and tenant concentration risks.
Ventas (VTR) reported earnings 30 days ago. What's next for the stock?
VTR is set to gain from rising healthcare spending amid an aging population. Accretive investments in the research portfolio and solid balance sheet bode well.
VTR is likely to gain from an aging population, rising healthcare expenses, favorable outpatient visit trends and accretive investments in its research portfolio.